Article Text
PDF
Statistics from Altmetric.com
Q In patients with chronic asthma, does optimising the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air (FENO) reduce asthma exacerbations and the daily dose more than using conventional criteria?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Allergy and immunology ★★★★☆☆☆ Respirology ★★★★★☆☆
METHODS
Design:
randomised controlled trial.
Allocation:
unclear.*
Blinding:
blinded (patients and physician who confirmed dose adjustment decisions).*
Follow up period:
12 months after optimal dose was established.
Setting:
university hospital in Dunedin, New Zealand.
Patients:
97 of 110 recruited patients who were 12–75 years of age (mean age 45 y, 63% women), had chronic asthma being managed in a primary care setting, and had been taking inhaled corticosteroids regularly for ⩾6 months with no change in dose in ⩽6 weeks. Exclusion criteria included ⩾4 courses of oral prednisone in ⩽12 months, admission to hospital for asthma in …
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Linked Articles
- Glossary